Why the study?
Although DOACs are increasingly used for left ventricular thrombosis, robust evidence supporting their use over VKAs is lacking, and optimal anticoagulation duration remains debated.
Vitamin K antagonists remain the standard of care for left ventricular thrombosis, highlighting a critical need for randomized trials to evaluate the efficacy and safety of DOACs in this setting.
No takes yet. Share an insight, caveat, or question.
VKAs remain preferred for LVT; leaves open DOAC role pending dedicated RCTs.
Catalani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: